Research Just Uncovered Another Undiscovered Benefit of GLP-1s—And It’s Not What You Think
A new study suggests the meds may reduce symptoms by up to 80 percent.
Reported by Women's Health Magazine.
GLP-1 medications like Ozempic and Zepbound have already racked up an impressive résumé — weight loss, type 2 diabetes management, migraine relief, and even potential Alzheimer's prevention. Now, according to Women's Health Magazine, a new study suggests they may also do something meaningful for the 7.5 million Americans living with psoriasis.
A scientific review published in JAMA Dermatology analyzed existing data on GLP-1 use in psoriasis patients and found that these medications were associated with reductions in both symptom severity and affected skin area — with some patients reporting improvements between 40 and 80 percent. Those with obesity or type 2 diabetes saw the most significant gains. "GLP-1 medications appear to have benefits beyond weight loss and diabetes control, including anti-inflammatory effects," said lead study author Samip Sheth, MD, a resident in Dermatology and Internal Medicine at the University of Minnesota. Caveats apply: most of the studies were small, short-term, and lacked control groups, so larger clinical trials are still needed before anyone rewrites the treatment playbook.
Why Your Weight-Loss Drug Might Be Helping Your Skin
Three mechanisms seem to be at play. First, GLP-1s broadly suppress inflammation in the body — and psoriasis, as Ife J. Rodney, MD, founding director of Eternal Dermatology + Aesthetics, explains, "is considered a systemic disease because it's related to inflammation." Second, these drugs appear to lower IL-17 levels, a class of pro-inflammatory proteins that existing psoriasis treatments already target, according to Cindy Wassef, MD, a dermatologist at Premier Health Associates. Third — and perhaps most intuitive — psoriasis is metabolically entangled with obesity and diabetes, the very conditions GLP-1s were built to treat. Gary Goldenberg, MD, assistant clinical professor of dermatology at Icahn School of Medicine at Mount Sinai, notes that significant weight loss from GLP-1 use reduces inflammatory signals produced by visceral fat, which in turn dials down the proteins driving psoriatic flares.
Nobody is prescribing Ozempic for a skin rash just yet. But the trajectory here is hard to ignore. "We have just started to scratch the surface when it comes to GLP-1s and their use in dermatology," said Wassef. Sheth puts it plainly: these drugs "could become an important adjunctive option for psoriasis, especially in patients with obesity or type 2 diabetes."
The bottom line: GLP-1s may be reshaping what we thought we knew about inflammation-driven disease — and psoriasis patients deserve to watch this research closely.
Read the original at Women's Health Magazine.
